CD19 and acute lymphoblastic leukemia: Blinatumomab is the only FDA-approved T-biAb and is a CD3/CD19 biAb for the treatment of relapsed or refractory B-cell progenitor acute lymphoblastic leukemia (B-ALL) patients [133].